Idorsia Ltd

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Subsidiary

Employees: -

Market Cap: $464M

Website: http://www.idorsia.com

Clinical Trials

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: Aprocitentan 10 mg
Drug: Placebo
Drug: Aprocitentan 5 mg
Drug: Aprocitentan 25 mg
Drug: Aprocitentan 50 mg
Drug: Lisinopril 20 mg

First Posted Date: 2015-11-13

Last Posted Date: 2022-11-23

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 1659

Registration Number: NCT02603809

Locations: 🇺🇸
LCC Medical Research Institute, Miami, Florida, United States
🇺🇸
Allied Biomedical Research Institute, INC, Miami, Florida, United States
🇺🇸
Midwest Institute for Clinical Research, Indianapolis, Indiana, United States

and more 83 locations

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo
Drug: ACT-541468 (hydrochloride salt)
Drug: ACT-541468 (free base)

First Posted Date: 2015-10-08

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 85

Registration Number: NCT02571855

Locations: 🇳🇱
Investigator Site, Leiden, Netherlands

Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage

Phase 2

Completed

Conditions: Aneurysmal Subarachnoid Hemorrhage

Interventions: Drug: Clazosentan

First Posted Date: 2015-09-25

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 25

Registration Number: NCT02560532

Locations: 🇫🇷
Site 1002, Bron, France
🇫🇷
Site 1004, Marseille, France
🇨🇭
Site 3001, Basel, Switzerland

and more 8 locations

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ACT-541468
Drug: Diltiazem

First Posted Date: 2015-08-18

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 14

Registration Number: NCT02526888

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

Phase 1

Terminated

Conditions: Healthy Subjects

Interventions: Drug: ACT-334441 2 mg
Drug: ACT-334441 4 mg
Drug: Atenolol
Drug: Placebo
Drug: Diltiazem ER

First Posted Date: 2015-06-24

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 10

Registration Number: NCT02479204

Locations: 🇫🇷
BIOTRIAL, Rennes, France

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Cenerimod
Drug: Matching placebo

First Posted Date: 2015-06-16

Last Posted Date: 2020-02-26

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 105

Registration Number: NCT02472795

Locations: 🇺🇦
Investigator Site, Zaporizhia, Ukraine

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-453859 1 mg
Drug: ACT-453859 3 mg
Drug: ACT-453859 10 mg
Drug: ACT-453859 30mg
Drug: ACT-453859 100 mg
Drug: ACT-453859 300 mg
Drug: ACT-453859 800 mg
Drug: Setipiprant 500 mg
Other: Placebo
Drug: Setipiprant 1000 mg

First Posted Date: 2015-03-06

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 88

Registration Number: NCT02381496

Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

First Posted Date: 2014-08-22

Last Posted Date: 2019-08-22

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 8

Registration Number: NCT02223871

Locations: 🇦🇺
Q-Pharm Clinics, Herston, Queensland, Australia

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-451840 50 mg
Drug: ACT-451840 200 mg
Drug: ACT-451840 (Dose to be determined)
Drug: ACT-451840 10 mg
Drug: ACT-451840 500 mg
Drug: ACT-451840 1000 mg
Drug: Placebo

First Posted Date: 2014-07-10

Last Posted Date: 2019-08-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 40

Registration Number: NCT02186002

Locations: 🇫🇷
OPTIMED Clinical Research, Gières, France

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ACT-389949 1 mg
Drug: ACT-389949 5 mg
Drug: ACT-389949 20 mg
Drug: ACT-389949 50 mg
Drug: ACT-389949 100 mg
Drug: ACT-389949 1000 mg
Drug: ACT-389949 200 mg
Drug: ACT-389949 500 mg
Drug: Placebo

First Posted Date: 2014-03-28

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 65

Registration Number: NCT02099071

Locations: 🇳🇱
QPS Netherlands BV, Groningen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy